Dr. Herbst on the Next Generation of Lung Cancer Trials

Video

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.

The next generation of lung cancer trials will try to match new biomarkers with new therapeutic agents.

The BATTLE trials, which began in 2005, had all patients freshly biopsied and randomized to 1 of 4 arms of therapy. Researchers began BATTLE-1 with hypotheses regarding biomarkers and outcomes and analyzed data in real time. This trial identified relationships between markers and drugs, including the correlation between VEGFR2 and activity of angiogenesis inhibitors.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD